The AbbVie Ventures-backed neurodegenerative disease treatment developer floated in the middle of its range having previously raised $129m in funding.

Prevail Therapeutics, a US-based gene therapy developer that counts pharmaceutical firm AbbVie as an investor, will raise $125m when it floats on the Nasdaq Global Market later today. The offering consists of just over 17.3 million shares priced at $17.00 each, at the midpoint of its $16 to $18 range. It values the company at…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.